Condition
Sarcoidosis
Sarcoidosis is an inflammatory disease in which clusters of immune cells (granulomas) form in organs, most commonly the lungs and lymph nodes.
Overview
Aetiology
Sarcoidosis is an inflammatory condition characterized by the formation of granulomas — small collections of immune cells — in one or more organs, most often the lungs and lymph nodes. Its exact cause is unknown, but it is thought to result from an exaggerated immune response to an environmental, infectious, or other antigenic trigger in a genetically susceptible person. It most commonly affects young and middle-aged adults.
Presentation
Symptoms
Presentation varies widely with the organs involved. Many cases are mild or found incidentally, while others cause a persistent dry cough, breathlessness, and chest discomfort from lung involvement. General symptoms such as fatigue, fever, night sweats, weight loss, and swollen lymph nodes are common, and skin lesions, eye inflammation, and joint pain may also occur.
Assessment
Diagnostic Considerations
Diagnosis is based on a combination of imaging (chest X-ray or CT showing characteristic changes), blood tests (which may show a raised serum ACE level and altered calcium), and biopsy demonstrating non-caseating granulomas while excluding other causes such as infection.
Assessment
Differential Diagnosis
Tuberculosis, fungal infections, lymphoma, and other granulomatous diseases can mimic sarcoidosis and must be excluded.
Context
Comorbidities
Sarcoidosis can be associated with pulmonary fibrosis and pulmonary hypertension, disturbances of calcium metabolism with kidney stones, eye disease, cardiac and neurological involvement, and an increased burden of fatigue and mood disturbance.
Supplementation
Supplementation (2)
Supplements, nutrients and compounds used for sarcoidosis.
ARA-290 (Cibinetide)
Non-erythropoietic EPO-derived peptide (innate repair receptor agonist)
An 11-amino-acid erythropoietin-derived peptide that activates the innate repair receptor without raising red-cell count; tested in small trials, never approved.
VIP (vasoactive intestinal peptide)
Neuropeptide (VPAC1/VPAC2 agonist)
An endogenous 28-amino-acid neuropeptide; its synthetic copy aviptadil is an approved erectile-dysfunction injection in parts of Europe.